US Pharma MarketingPartner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancer
With the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that fall under its U.S. national priority pilot. With the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that fall under its U.S. national priority pilot. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources…
With the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that fall under its U.S. national priority pilot.
Source: FiercePharma